{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Ji W"],"funding":["US Government National Institutes of Health","NCI NIH HHS"],"pagination":["116613"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11316633"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["276"],"pubmed_abstract":["Cyclin-dependent kinase 7, along with cyclin H and MAT1, forms the CDK-activating complex (CAK), which directs cell cycle progression via T-loop phosphorylation of cell cycle CDKs. Pharmacological inhibition of CDK7 leads to selective anti-cancer effects in cellular and in vivo models, motivating several ongoing clinical investigations of this target. Current CDK7 inhibitors are either reversible or covalent inhibitors of its catalytic activity. We hypothesized that small molecule targeted protein degradation (TPD) might result in differentiated pharmacology due to the loss of scaffolding functions. Here, we report the design and characterization of a potent CDK7 degrader that is comprised of an ATP-competitive CDK7 binder linked to a CRL2<sup>VHL</sup> recruiter. JWZ-5-13 effectively degrades CDK7 in multiple cancer cells and leads to a potent inhibition of cell proliferation. Additionally, compound JWZ-5-13 displayed bioavailability in a pharmacokinetic study conducted in mice. Therefore, JWZ-5-13 is a useful chemical probe to investigate the pharmacological consequences of CDK7 degradation."],"journal":["European journal of medicinal chemistry"],"pubmed_title":["Discovery of bivalent small molecule degraders of cyclin-dependent kinase 7 (CDK7)."],"pmcid":["PMC11316633"],"funding_grant_id":["R01 CA218278","R01 CA258553","R01CA258553-04","R01 CA179483"],"pubmed_authors":["Jiang J","Lu W","Jiang F","Yuan L","Chung M","Hinshaw SM","Mills CE","Jiang Z","Zhang T","Gray NS","Byun WS","Ji W","He Z","Du G","Bradshaw GA"],"additional_accession":[]},"is_claimable":false,"name":"Discovery of bivalent small molecule degraders of cyclin-dependent kinase 7 (CDK7).","description":"Cyclin-dependent kinase 7, along with cyclin H and MAT1, forms the CDK-activating complex (CAK), which directs cell cycle progression via T-loop phosphorylation of cell cycle CDKs. Pharmacological inhibition of CDK7 leads to selective anti-cancer effects in cellular and in vivo models, motivating several ongoing clinical investigations of this target. Current CDK7 inhibitors are either reversible or covalent inhibitors of its catalytic activity. We hypothesized that small molecule targeted protein degradation (TPD) might result in differentiated pharmacology due to the loss of scaffolding functions. Here, we report the design and characterization of a potent CDK7 degrader that is comprised of an ATP-competitive CDK7 binder linked to a CRL2<sup>VHL</sup> recruiter. JWZ-5-13 effectively degrades CDK7 in multiple cancer cells and leads to a potent inhibition of cell proliferation. Additionally, compound JWZ-5-13 displayed bioavailability in a pharmacokinetic study conducted in mice. Therefore, JWZ-5-13 is a useful chemical probe to investigate the pharmacological consequences of CDK7 degradation.","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Oct","modification":"2026-06-04T04:25:54.649Z","creation":"2026-05-04T03:14:32.873Z"},"accession":"S-EPMC11316633","cross_references":{"pubmed":["39004018"],"doi":["10.1016/j.ejmech.2024.116613"]}}